AbCellera and AbbVie Partner to Advance New Antibody Therapies
December 15 2022 - 6:00AM
Business Wire
AbCellera (Nasdaq: ABCL) announced today that it has entered
into a multi-year, multi-target strategic collaboration with AbbVie
Inc. (NYSE: ABBV). The partnership will leverage AbCellera’s
antibody discovery and development engine to deliver optimized
development candidates for up to five targets selected by AbbVie
across multiple indications.
“This collaboration with AbbVie is another example of how
AbCellera can extend the R&D capabilities for enabled
pharmaceutical companies,” said Carl Hansen, Ph.D., founder and CEO
of AbCellera. “Together with AbbVie, we aim to tackle some of the
most difficult antibody discovery problems to help address
patients’ most serious health issues.”
Under the terms of the agreement, AbbVie has the right to
develop and commercialize therapeutic antibodies resulting from the
collaboration. AbCellera will receive research payments and is
eligible to receive downstream clinical and commercial milestone
payments and royalties on net sales of products.
About AbCellera Biologics Inc. AbCellera is a
technology company that searches, decodes, and analyzes natural
immune systems to find antibodies that its partners can develop
into drugs to prevent and treat disease. AbCellera partners with
drug developers of all sizes, from large pharmaceutical to small
biotechnology companies, empowering them to move quickly, reduce
cost, and tackle the toughest problems in drug development. For
more information, please visit www.abcellera.com.
AbCellera Forward-Looking Statements This press
release contains forward-looking statements, including statements
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The forward-looking
statements are based on management’s current beliefs and
assumptions and on information currently available to management.
All statements contained in this release other than statements of
historical fact are forward-looking statements, including
statements regarding our ability to develop, commercialize and
achieve market acceptance of our current and planned products and
services, our research and development efforts, and other matters
regarding our business strategies, use of capital, results of
operations and financial position, and plans and objectives for
future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
Source: AbCellera Biologics Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221215005196/en/
Media: Jessica Yingling, Ph.D.; media@abcellera.com,
+1(236)521-6774 Business Development: Murray McCutcheon, Ph.D.;
bd@abcellera.com, +1(604)559-9005 Investor Relations: Josephine
Hellschlienger, Ph.D.; ir@abcellera.com, +1(778)729-9116
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From Apr 2024 to May 2024
AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart
From May 2023 to May 2024